Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol
- 1 February 2003
- journal article
- research article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 13 (4) , 333-336
Abstract
Background:In adults with heart failure, neurohormonal overstimulation is related to the progression of the disease, and influences prognosis. β-blockers, which modulate neurohormonal activation, now play an essential role in the pharmacological management of heart failure in adults, but their use in children is very limited.Patients and Methods:To investigate the effects of carvedilol administration on neurohormonal activation and left ventricular function, carvedilol was added to standard treatment for heart failure in 9 patients with dilated cardiomyopathy due to heart muscle disease. Standard treatment has been in place for at least 1 month. The protocol consisted in a baseline evaluation to assess neurohormonal activation, and echocardiographic evaluation of left ventricular function. This was followed by a final evaluation at 12 months from carvedilol loading. Carvedilol was started at 0.05 mg/kg/day, and increased every two weeks until the target dose of 0.8 mg/kg/day was reached.Results:Carvedilol administration was associated with a significant reduction in plasma norepinephrine (p = 0.00001), dopamine (p = 0.0001), aldosterone (p = 0.00001) and activation of the renin-angiotensin system (p = 0.0006). Similar reductions in vanilmandelic and homovanillic acid were noted. After 12 months, a positive remodeling took place, with significant reductions in end-diastolic (p = 0.004) and end-systolic diameters (p = 0.009), and an increase in left ventricular ejection fraction (p = 0.001). No adverse effects needing reduction or interruption in the dosage were noted in the run-in phase, nor in the period of maintenance.Conclusion:Carvedilol is a safe complement to standard therapy for heart failure in children, allowing a significant reduction of neurohormonal activation with evident benefits on both ventricular function and the clinical condition.Keywords
This publication has 21 references indexed in Scilit:
- The pediatric randomized carvedilol trial in children with chronic heart failure: Rationale and designAmerican Heart Journal, 2002
- Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunctionThe Journal of Heart and Lung Transplantation, 2002
- β-blockers, angiotensin II, and ACE inhibitors in patients with heart failureThe Lancet, 2001
- Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilolAmerican Heart Journal, 2001
- Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysisAmerican Heart Journal, 2001
- Carvedilol as therapy in pediatric heart failure: An initial multicenter experienceThe Journal of Pediatrics, 2001
- Neurohormonal Activation, Oxygen Free Radicals, and Apoptosis in the Pathogenesis of Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1998
- Adrenergic effects on the biology of the adult mammalian cardiocyte.Circulation, 1992
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984
- Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failureThe American Journal of Cardiology, 1982